LBRX News

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer

LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference

LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates

LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms